Alessandro Passardi
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori(IT)Istituti di Ricovero e Cura a Carattere Scientifico(IT)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial(2020)314 cited
- → Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial(2005)274 cited
- → Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?(2018)265 cited
- → Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial(2022)251 cited
- → Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs(2013)220 cited